弥散加权MRI预测胰腺导管腺癌下一代测序肿瘤细胞密度及手术切除后预后
回顾性纳入105例手术切除的胰腺导管腺癌患者,术前MRI含DWI。基于NGS的较高肿瘤细胞密度(≥30%)与更差无病生存相关(HR 1.599),改良ADC值(肿瘤ADC/脾ADC)与肿瘤细胞密度相关(OR 0.068),改良ADC≤1.40者中位无病生存显著更短(8个月 vs 16个月)。
要点
- 改良ADC值≤1.40的PDAC中位DFS为8个月,高于该值者为16个月
- 基于NGS的肿瘤细胞密度≥30%与更差DFS独立相关(HR 1.599)
- 改良ADC值与肿瘤细胞密度显著相关(OR 0.068,P=0.002)
核心结论
- 基于NGS的较高肿瘤细胞密度可能是胰腺癌切除后不良预后因素,DWI衍生的改良ADC值可能有助于预测肿瘤细胞密度及术后复发结局。
研究设计与样本
- 回顾性研究,纳入105例手术切除的PDAC患者,术前接受含DWI的MRI检查;肿瘤细胞密度采用分子技术和生物信息学方法测量;DFS和OS预测采用Cox比例风险模型。
关键影像表现/征象
- PDAC的ADC值及改良ADC值(PDAC的ADC值与脾的ADC值之比)被用于预测较高肿瘤细胞密度(≥30%)和不良预后。
诊断标准与关键数值
- 改良ADC值预测肿瘤细胞密度的比值比OR为0.068(95%CI 0.012-0.372),P=0.002。
- 改良ADC值≤1.40(截断值)的PDAC中位DFS为8个月(95%CI 4-12),改良ADC值>1.40者为16个月(95%CI 10-29),HR 1.713(95%CI 1.073-2.735),log-rank P=0.024。
- 较高T分期(T3/4)与更差DFS相关:HR 7.720(95%CI 1.072-55.612),P=0.048。
- 较高肿瘤细胞密度与更差DFS相关:HR 1.599(95%CI 1.003-2.548),P=0.048。
临床应用与阅片要点
- 术前MRI含DWI时可测量PDAC的ADC值并计算改良ADC值(肿瘤ADC/脾ADC),用于评估肿瘤细胞密度及复发风险。
- 改良ADC值≤1.40提示中位DFS较短(8个月 vs 16个月),可作为预后分层参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To identify features on preoperative MR imaging with diffusion-weighted imaging (DWI) for predicting next-generation sequencing (NGS)-based tumor cellularity and patient outcome after surgical resection of pancreatic ductal adenocarcinoma (PDAC).
METHODS: This retrospective study included 105 patients with surgically resected PDAC who underwent preoperative MR imaging with DWI. Tumor cellularity was measured using molecular techniques and bioinformatics methods. Clinico-pathologic findings including tumor T stage for predicting disease-free survival (DFS) and overall survival (OS) were identified using Cox proportional hazards model. Important MR imaging findings including apparent diffusion coefficient (ADC) value of PDAC and modified ADC value (the ratio of the ADC value of PDAC to the ADC value of the spleen) for predicting higher tumor cellularity (≥ 30%) and poor prognosis were also identified.
RESULTS: The median DFS and OS were 12.0 months [95% confidence interval (CI), 8.0-17.0] and 22.0 months (95% CI, 18.0-29.0), respectively. Higher T stage (T3/4) [hazard ratio (HR), 7.720, (95% CI 1.072, 55.612); p = 0.048] and higher tumor cellularity [HR, 1.599 (95% CI, 1.003-2.548); p = 0.048] were significantly associated with worse DFS. Among MR imaging features, the modified ADC value was significantly associated with tumor cellularity [odds ratio, 0.068 (95% CI, 0.012-0.372); p = 0.002], and PDAC with lower modified ADC value [≤ 1.40 (cutoff value)] showed significantly shorter median DFS than PDAC with higher modified ADC value [8 months (95% CI, 4-12) vs. 16 months (95% CI, 10-29); HR, 1.713 (95% CI, 1.073-2.735), log-rank p = 0.024].
CONCLUSION: Higher NGS-based tumor cellularity may be a negative prognostic factor in pancreatic cancer after resection, and modified ADC value derived from DWI could be helpful in predicting tumor cellularity and patient surgical outcome with regard to recurrence.
引用
- Jeon SK, Jang JY, Kwon W, et al. Diffusion-weighted MR imaging in pancreatic ductal adenocarcinoma: prediction of next-generation sequencing-based tumor cellularity and prognosis after surgical resection. Abdom Radiol (NY). 2021. PMID: 34143259. doi:10.1007/s00261-021-03177-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。